Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting ...
Why Do Some Patients With Early-Stage Lung Cancer Not Receive Surgical Treatment Despite Guidelines?
A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...
Circular tumor DNA (ctDNA) positivity is associated with poorer survival and higher recurrence rates among patients with non–small cell lung cancer (NSCLC), but early detection may allow for timely ...
About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...
Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...
Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...
In this study, researchers evaluated patients who had incomplete cCRT or experienced progression during or within 42 days of receiving cCRT, with an aim of identifying risk factors for these outcomes.
Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results